DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1878 development of hepatocellular carcinoma: A molecular epidemiological
approach. Mutat Res, 1999, 428:187–196.
Szabo E. Selecting targets for cancer prevention: Where do we
go from here? Nat Rev Cancer, 2006, 6:867–874.
Tsien RY, Pozzan T, Rink TJ. Calcium activities and fluxes inside
small intact cells as measured with intracellularly trapped
chelators. Adv Cyclic Nucleotide Protein Phosphorylation Res,
1984, 17:535–541.
Vaziri ND, Khan M. Interplay of reactive oxygen species and
nitric oxide in the pathogenesis of experimental lead-induced
hypertension. Clin Exp Pharmacol Physiol, 2007, 34:
920–925.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen
vs raloxifene on the risk of developing invasive breast cancer
and other disease outcomes: The NSABP Study of
Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006,
295:2727–2741.
Waalkes MP, Liu J, Diwan BA. Transplacental arsenic carcinogenesis
in mice. Toxicol Appl Pharmacol, 2007, 222:271–280.
Waisberg M, Joseph P, Hale B, Beyersmann D. Molecular and
cellular mechanisms of cadmium carcinogenesis. Toxicology,
2003, 192:95–117.
Wasserman GA, Liu X, Parvez F, et al. Water arsenic exposure
and intellectual function in 6-year-old children in Araihazar,
Bangladesh. Environ Health Perspect, 2007, 115:285–289.
Wattenberg LW. Chemoprophylaxis of carcinogenesis: A review.
Cancer Res, 1966, 26:1520–1526.
William WN, Heymach JV, Kim ES, Lippman SM. Molecular
targets for cancer chemoprevention. Nat Rev Drug Discov,
2009, 8:213–225.
Wogan GN, Hecht SS, Felton JS, et al. Environmental and chemical
carcinogenesis. Semin Cancer Biol, 2004, 14:473–486.
Woolley DE. A perspective of lead poisoning in antiquity and
the present. Neurotoxicology, 1984, 5:353–361.
SECTION IX
SPECIAL SYSTEMS PHARMACOLOGY